Bond.az White LogoBond.az Black Logo

Marvell price target raised to $200 by RBC on optical strength

RBC Capital raised Marvell Technology price target to $200, citing optical business strength. AI networking and custom XPU trends support growth.

John Smith
ByJohn Smith- Senior Editor
|
0

RBC Capital raised its price target on Marvell Technology stock to $200 from $170 while maintaining an Outperform rating.

The stock currently trades at $177.95, up 110% year-to-date and near its 52-week high of $182.31.

The firm expects Marvell (NASDAQ:MRVL) to deliver a slight beat and raise guidance, with upside driven primarily by its optical business.

Analysts view Nvidia's recent investment as validation of Marvell's optical connectivity leadership. Custom XPU trends appear solid, though near-term upside may be limited due to tight wafer supply.

According to Bond.az data, Marvell is trading above its Fair Value, despite strong revenue growth of 42%.

RBC Capital expects Marvell to remain a key supplier to Amazon, and views AWS's recent OpenAI and Anthropic partnerships as material long-term positives. Microsoft's XPU appears on track for an early 2027 ramp.

Marvell has multiple XPU-attach custom engagements across hyperscalers. RBC Capital expects topline momentum to sustain for the next two to three years.

In other news, Marvell announced the acquisition of Polariton Technologies. Bank of America Securities also raised its price target to $200. However, JPMorgan dismissed reports that Marvell secured TPU business from Google.

More News
Today / 13:34
|
741

Jefferies Reiterates Buy on Biogen Stock

Jefferies reiterates Buy rating on Biogen stock with $210 target following promising Phase II Alzheimer's data.

0
Today / 13:03
|
769

Morgan Stanley Upgrades Assurant Stock Rating

Morgan Stanley upgrades Assurant stock to Overweight, raises price target to $285. Strong earnings and growth outlook highlighted.

0
Today / 12:41
|
890

Biogen Stock Rises as Stifel Maintains Buy

Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.

0
Today / 12:32
|
422

Compass Point raises Nebius target to $260 on strong Q1

Compass Point raised Nebius price target to $260 on strong Q1 results. ARR and AI Cloud revenue surge. Read more on Bond.az.

0
Today / 11:44
|
476

H.C. Wainwright Reiterates Immunic Stock Rating

H.C. Wainwright maintains Buy rating and $22 price target on Immunic stock. The company awaits pivotal MS drug trial results. Read more on Bond.az.

0
Today / 11:43
|
800

H.C. Wainwright Reiterates Kamada Buy Rating

H.C. Wainwright reaffirms Buy rating on Kamada with $13 target. Kamada expects double-digit revenue growth in 2026.

0
Today / 11:42
|
902

Titan Mining Price Target Cut by H.C. Wainwright

H.C. Wainwright cuts Titan Mining price target to $6.50, maintains Buy. Stock up 357% in a year, but Bond.az flags overvaluation risk.

0
Today / 11:41
|
334

Avino Silver & Gold Target Raised by Analyst

H.C. Wainwright raises Avino Silver & Gold price target to $13.00 after strong earnings report with 109% revenue growth.

0
Today / 11:05
|
280

Truist reiterates Buy on Uber stock

Truist Securities reiterates Buy on Uber stock with $112 target, citing AV strength and growth potential.

0
Today / 11:04
|
241

CrowdStrike target raised to $621 by BTIG | Bond.az

BTIG raises CrowdStrike stock price target to $621, citing platform growth and partner feedback. Stock up 20% YTD.

0
Today / 11:02
|
419

Truist raises CG Oncology target to $82 on NMIBC data

Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.

0
Today / 11:01
|
308

Morgan Stanley cuts Amcor price target to $42

Morgan Stanley cuts Amcor price target to $42 from $44, citing lower EPS and EBIT forecasts. Stock near 52-week low.

0
...